reports
- Jerôme Bodin
ODDO BHF Small & MIDCAP MORNING NEWS - 03/05/2024
Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...
- Jerôme Bodin
ODDO BHF Small & MIDCAP MORNING NEWS - 05/03/2024
Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...
- Gautier Le Bihan
2CRSI : Guidance raised for FY 2023-24, revenue expected above € 190m
>Upward revision to revenue and EBITDA for FY 2023-24 (16 months) - 2CRSi yesterday evening issued a press release announcing an increase in its financial targets for FY 2023-24 to end-June 2024 (16 months). Whereas at the announcement of the capital increase (12 March 2024) the company had guided to FY 2023-24 revenue of € 150m with an EBITDA margin above 3%, it announced yesterday evening that it was raising its guidance for the financial year to revenue of € 190m w...
- Gautier Le Bihan
2CRSI : Révision à la hausse des guidances pour l’exercice 2023-2024, ...
>Révision à la hausse du CA et de l’EBITDA pour l’exercice 2023-204 (16 mois) - Hier soir 2CRSi a publié un communiqué pour annoncer une révision à la hausse de ses objectifs financiers pour l’exercice 2023-2024 se terminant à fin juin 2024 (16 mois). Alors que la société guidait lors de l’annonce de l’augmentation de capital (12 mars 2024) sur un CA 2023-2024 de 150 M€ avec une marge d’EBITDA supérieure à 3%, elle relève sa guidance pour ce même exercice à 190 M€ ave...
BioSenic S.A. : Information on the total number of voting rights and ...
BioSenic S.A. : Information on the total number of voting rights and shares PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, April 30, 2024, 7.00 am CEST – (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published in accordance with Article 15 of the Belgian law of 2 May 2007 on the publication of major shareholdings in issuers...
BioSenic publie sur son site web le plan de restructuration soumis au ...
BioSenic publie sur son site web le plan de restructuration soumis au tribunal des entreprises de Nivelles COMMUNIQUE DE PRESSE – INFORMATION PRIVILIGIEE Mont-Saint-Guibert, Belgique, le 26 avril 2024 à 17h30 CEST – (Euronext Bruxelles et Paris: BIOS), la société en phase clinique spécialisée dans les maladies auto-immunes et inflammatoires graves, dans le cadre du plan de restructuration global annoncé le 11 avril 2024, annonce aujourd'hui la publication sur son site internet de la documentation suivante : Le plan de restructuration couvrant les années 2024-2030 soumis au Tribunal...
BioSenic publishes on its website the restructuring plan submitted to ...
BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles PRESS RELEASE - PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, 26 April 2024, 17:30 CET – (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases, as part of the global restructuring plan announced on 11 April 2024, today announces the publication on its website of the following documentation : The restructuring plan covering the years 2024-2030 submitted to the Enterprise Court of Nivelles – accessible via th...
- Anthony Dick
- Michael Foundoukidis
ODDO BHF Small & MIDCAP MORNING NEWS - 04/26/2024 Date Performance sin...
Deutz is a leading non-captive engine manufacturer for a wide range of customer industries with a strong and very well-known brand. The company will enter a profitable growth period soon (CAGR 2023-26e sales 8%, EPS 18%). We initiate coverage with an Outperform rating and a target price of € 7.9, reflecting >40% upside from here. - ...
PROX PROXIMUS SA DE DROIT PUBLIC
SOP SOPRA STERIA GROUP SA
BFIT BASIC-FIT NV
NXI NEXITY SA CLASS A
MF WENDEL SE
SBS STRATEC SE
KORI KORIAN SA
STF STEF
ALCLA CLASQUIN SA
ASY ASSYSTEM SA
SWP SWORD GROUP SE
CGM CEGEDIM SA
SRP SRP GROUPE SA
MTU MANITOU BF SA
FII LISI SA
GBT GUERBET SA
ATE ALTEN SA
FR VALEO SE
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
SAVE SAVENCIA SA
MBWS MARIE BRIZARD WINE & SPIRITS SA
SOC SUBSEA 7 S.A.
TIETO TIETOEVRY OYJ
ARCAD ARCADIS NV
SESL SES-IMAGOTAG SA
LIGHT SIGNIFY NV
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
CSM CORBION NV
VLTSA VOLTALIA
IBG IBERPAPEL GESTION S.A.
TEC TECHNIPFMC PLC
FTG111 FLATEXDEGIRO AG
BFSA BEFESA SA
SAB BANCO DE SABADELL SA
RBO ROCHE BOBOIS INTERNATIONAL SAS
GRP GREENCOAT RENEWABLES
- Anthony Dick
- Michael Foundoukidis
ODDO BHF Small & MIDCAP MORNING NEWS - 26/04/2024
Deutz is a leading non-captive engine manufacturer for a wide range of customer industries with a strong and very well-known brand. The company will enter a profitable growth period soon (CAGR 2023-26e sales 8%, EPS 18%). We initiate coverage with an Outperform rating and a target price of € 7.9, reflecting >40% upside from here. - ...
PROX PROXIMUS SA DE DROIT PUBLIC
SOP SOPRA STERIA GROUP SA
BFIT BASIC-FIT NV
NXI NEXITY SA CLASS A
MF WENDEL SE
SBS STRATEC SE
KORI KORIAN SA
STF STEF
ALCLA CLASQUIN SA
ASY ASSYSTEM SA
SWP SWORD GROUP SE
CGM CEGEDIM SA
SRP SRP GROUPE SA
MTU MANITOU BF SA
FII LISI SA
GBT GUERBET SA
ATE ALTEN SA
FR VALEO SE
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
SAVE SAVENCIA SA
MBWS MARIE BRIZARD WINE & SPIRITS SA
SOC SUBSEA 7 S.A.
TIETO TIETOEVRY OYJ
ARCAD ARCADIS NV
SESL SES-IMAGOTAG SA
LIGHT SIGNIFY NV
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
CSM CORBION NV
VLTSA VOLTALIA
IBG IBERPAPEL GESTION S.A.
TEC TECHNIPFMC PLC
FTG111 FLATEXDEGIRO AG
BFSA BEFESA SA
SAB BANCO DE SABADELL SA
RBO ROCHE BOBOIS INTERNATIONAL SAS
GRP GREENCOAT RENEWABLES
- Aurelien Sivignon
VusionGroup : Q1 2024 in line and order entries still trending favoura...
>Much faster growth in the USA, offsetting the downturn in Europe - VusionGroup’s Q1 revenue figures came out in line with our forecasts, with revenue growing by 12% y-o-y to € 178m (vs € 176me). On a reported IFRS basis (post-adjustment for the WMT contract, which for the record has no cash impact), sales reached € 172m, i.e. +8% y-o-y. The EMEA region (60% of Q1 revenue) posted a 18% decline to € 106m, reflecting the gradual completion of the Lidl roll-out, which wa...
- Aurelien Sivignon
VusionGroup : T1 2024 en ligne et prises de commandes toujours bien or...
>Forte accélération des USA qui compense la baisse en Europe - Le T1 de VusionGroup ressort en ligne avec nos attentes avec une progression du CA de 12% y-o-y à 178 M€ (vs 176 M€e). En publié IFRS (post ajustement sur contrat WMT, sans impact cash pour rappel), le CA s’établit à 172 M€ i.e. +8% y-o-y. EMEA (60% du CA T1) est en baisse de 18% à 106 M€ considérant la fin progressive du déploiement Lidl qui contribuait largement au CA N-1. La zone Amériques et Asie-Pacif...
BioSenic postpones its annual general meeting of the shareholders and ...
BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023 PRESS RELEASE - PRIVILEGED INFORMATION In view of the restructuring plan announced on April 11, 2024, BioSenic has decided to postpone the publication of its 2023 annual report as well as its annual general meeting of shareholders, so that the Enterprise Court of Nivelles can make a decision before the completion of the annual formalities. The Company believes that this postponement is preferable to ensure that the financial statements can be prepared on a going...
BioSenic reporte son assemblée générale annuelle des actionnaires et f...
BioSenic reporte son assemblée générale annuelle des actionnaires et fournit des chiffres financiers temporaires non-audités pour 2023 COMMUNIQUE DE PRESSE – INFORMATION PRIVILIGIEE Compte tenu du plan de restructuration annoncé le 11 avril 2024, BioSenic a décidé de reporter la publication de son rapport annuel 2023 ainsi que son assemblée générale annuelle des actionnaires, afin que le Tribunal de l'entreprise de Nivelles puisse prendre une décision avant l'accomplissement des formalités annuelles. La société estime que ce report est préférable pour s'assurer que les états financiers pe...
BioSenic S.A. : Transparency notifications received from François Rie...
BioSenic S.A. : Transparency notifications received from François Rieger PRESS RELEASE – REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, April 18, 2024, 7am CET – (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received transparency notifications from François Rieger. Details of the notifications can be found below and the full versions of the transparency declarations are available ...
BioSenic S.A. : Notifications de transparence reçues de la part de Fr...
BioSenic S.A. : Notifications de transparence reçues de la part de François Rieger COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE Article 14 de la loi du 2 mai 2007 relative à la publicité des participations importantes Mont-Saint-Guibert, Belgique, le 18 avril 2024 à 7h00 CET – (Euronext Bruxelles et Paris : BIOS), la société en phase clinique spécialisée dans les maladies auto-immunes et inflammatoires graves et dans la thérapie cellulaire, annonce aujourd’hui la réception de notifications de transparence de François Rieger. Les détails des notifications peuvent être trou...
BioSenic provides further information on its restructuring plan
BioSenic provides further information on its restructuring plan PRESS RELEASE - PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, 12 April 2024, 12:00 CET – (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, as part of the global restructuring plan announced on 11 April 2024, provides information on (i) the Company's current debt position and the potential impact of the plan on this position and (ii) links to the Company's website to consult the conversion terms and conditions offered to h...
BioSenic fournit des informations complémentaires sur son plan de rest...
BioSenic fournit des informations complémentaires sur son plan de restructuration COMMUNIQUE DE PRESSE – INFORMATION PRIVILEGIEE Mont-Saint-Guibert, Belgique, le 12 avril 2024 à 12h00 CET – (Euronext Bruxelles et Paris: BIOS), la société en phase clinique spécialisée dans les maladies auto-immunes et inflammatoires graves et dans la thérapie cellulaire renseigne, dans le cadre du plan de restructuration global annoncé le 11 avril 2024, (i) la situation d'endettement actuelle de la Société et les conséquences potentielles du plan sur celle-ci et (ii) renvoie vers le site internet de l...
BioSenic and its restructuring practitioner (Me Yves Brulard) submit a...
BioSenic and its restructuring practitioner (Me Yves Brulard) submit a global restructuring plan covering the years 2024-2030 to the Enterprise Court of Nivelles PRESS RELEASE - PRIVILEGED INFORMATION A final circular of the creditors on the basis of XX 83/23 of the Economic Law Code (ELC) will take place before the Court grants authorisation, in accordance with article XX 83/26 of the ELC, to submit the plan to the vote of each class of creditors and to homologation. The creditors will be aware of the plan, which by law contains information that could be privileged. Mont-Saint-Guibert,...
BioSenic et son praticien de la restructuration (Me Yves Brulard) soum...
BioSenic et son praticien de la restructuration (Me Yves Brulard) soumettent un plan de restructuration global engageant les années 2024-2030 au Tribunal de l’entreprise de Nivelles COMMUNIQUE DE PRESSE – INFORMATION PRIVILEGIEE Une circularisation finale des créanciers sur base de XX 83/23 du Code de Droit Economique (CDE) va intervenir avant que le Tribunal n’autorise, conformément à l'article XX 83/26 du CDE, de soumettre le plan au vote de chaque classe de créanciers et l’homologation. Les créanciers auront connaissance du plan qui contient en vertu de la loi des informations qui po...
- Bruno Cavalier
- Emira Sagaama
- Stephane Beyazian
ODDO BHF Small & MIDCAP MORNING NEWS - 09/04/2024 Date Performance dep...
Nous réitérons notre recommandation Surperformance (conviction Midcap Europe) avec un objectif de cours et des prévisions de résultats relevés. L’optimisme est de rigueur sur les perspectives d’activité, les marges offrent encore un potentiel d’amélioration, le bilan est sous-leveragé, les multiples de valorisation restent attractifs et le fondateur achète des actions. - ...
ETL EUTELSAT COMMUNICATIONS SA
PROX PROXIMUS SA DE DROIT PUBLIC
ATO ATOS SE
KPN ROYAL KPN NV
ORA ORANGE SA
EN BOUYGUES SA
SDG SYNERGIE SA
UTDI UNITED INTERNET AG
GAMA GAMMA COMMUNICATIONS
BAMNB KONINKLIJKE BAM GROEP NV
DTE DEUTSCHE TELEKOM AG
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
TIT TELECOM ITALIA S.P.A.
CLNX CELLNEX TELECOM S.A.
FNTN FREENET AG
VOD VODAFONE GROUP PLC
OBEL ORANGE BELGIUM SA
TEF TELEFONICA SA
NFN NFON AG
ALFEN ALFEN NV
DRI 1&1 DRILLISCH AG
DEME DEME GROUP NV
LHYFE LHYFE S.A.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.